Consistent with these findings, adoptive transfer of OT-I cells with CRISPR–Cas9-mediated Creb1 knockout led to attenuated anti-tumour effects in mice compared with control OT-I cells and did not respond to TVA diet (Fig. 4f, right). The gene discussed is CREB1; the disease is neoplasm.